Literature DB >> 20153576

Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors.

Yan Li1, Kazuhiro Tanaka, Xueli Fan, Fumihiko Nakatani, Xu Li, Tomoyuki Nakamura, Minoru Takasaki, Shunsaku Yamamoto, Yukihide Iwamoto.   

Abstract

The chromosomal translocation t(11;22)(q24;q12) generates the EWS-Fli1 fusion gene, which contributes to the development of Ewing Family Tumors (EFTs). Although p53 mutations are found only in 5-20% of EFTs, the p53 pathway is thought to be abrogated in EFTs. The role of EWS-Fli1 in the p53 pathway in the tumor is still poorly understood. In this study, using immunoprecipitation and co-localization, we show that EWS-Fli1 interacts with p53 within the nucleus in vivo. The introduction of EWS-Fli1 resulted in significant reduction of promoter activities and mRNA levels of p21 and mdm2, meanwhile it canceled p53-dependent growth suppression. In contrast, knockdown of EWS-Fli1 expression mediated by small interfering RNAs (siRNA) also augmented the induction of p21 and mdm2 in response to DNA damage. Furthermore, using serial deletion constructs of the EWS-Fli1 fusion protein, we determined that EWS-Fli1 binding to p53 as well as inhibition of p21 and mdm2 promoter activities was mediated by its N-terminal domain (amino acid residues 65-109). These observations suggest that the N-terminal region of EWS-Fli1 might associate with p53 and impair its transcriptional activity, subsequently inhibiting the expression of its downstream genes. These results might provide new insight into the oncogenesis of EFTs by EWS-Fli1 via the inhibition of p53 function. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153576     DOI: 10.1016/j.canlet.2010.01.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

3.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

Review 4.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

5.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

Review 6.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 7.  Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

Authors:  Balaji Ramachandran; Thangarajan Rajkumar; Gopal Gopisetty
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 8.  Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors.

Authors:  Monica Cantile; Laura Marra; Renato Franco; Paolo Ascierto; Giuseppina Liguori; Annarosaria De Chiara; Gerardo Botti
Journal:  Med Oncol       Date:  2013-01-18       Impact factor: 3.064

9.  miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Keiichiro Iida; Jun-Ichi Fukushi; Yoshihiro Matsumoto; Yoshinao Oda; Yusuke Takahashi; Toshifumi Fujiwara; Yuko Fujiwara-Okada; Mihoko Hatano; Akira Nabashima; Satoshi Kamura; Yukihide Iwamoto
Journal:  Cancer Cell Int       Date:  2013-03-04       Impact factor: 5.722

10.  Potential molecular targets for Ewing's sarcoma therapy.

Authors:  Babu Jully; Thangarajan Rajkumar
Journal:  Indian J Med Paediatr Oncol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.